Improving the care of patients discharged following a pulmonary embolism, in line with NICE Guidelines [NG158]
Project started out as audit looking into how to improve discharge process for patients following a PE, however upon understanding limitations of care provided on discharge, practice was changed in line with NICE guidelines to ensure safest possible discharge for these patients. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - July 2, 2021 Category: Consumer Health News Source Type: news
Bile pulmonary embolism-related sudden death following an abdominal firearm injury: an autopsy case report and review of literature - Fnon NF, Seleim HM, Abdel-Wahab MS, Sobh ZK.
This article reports a fa... (Source: SafetyLit)
Source: SafetyLit - June 28, 2021 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Aidoc and Icometrix pair up for stroke care
Artificial intelligence (AI) software developer Aidoc has joined forces wit...Read more on AuntMinnie.comRelated Reading:
Radiology Partners joins forces with Aidoc
Aidoc unveils AI notification application for PE
Icometrix launches AI software for ischemic stroke
Aidoc and Imbio team up on AI for pulmonary embolism
Icometrix names new chief commercial officer
Icometrix nets FDA OK for epilepsy detection software (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 22, 2021 Category: Radiology Source Type: news
What Is the Survival Rate of a Pulmonary Embolism
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 18, 2021 Category: General Medicine Source Type: news
Postop chylothorax treated with intranodal lymphangiography, ethiodized oil
(American Roentgen Ray Society) According to AJR, high-dose intranodal lymphangiography with ethiodized oil is a safe and effective procedure for treating high-output postsurgical chylothorax with chest tube removal in 83% of patients. Previously, no data were available on the safety or benefits of injecting higher doses of ethiodized oil to treat patients with refractory postoperative chylothorax. No early or late clinically relevant complications, including symptomatic pulmonary or paradoxical embolism, were recorded for any of the patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 14, 2021 Category: International Medicine & Public Health Source Type: news
Are ventilation scans needed in pulmonary embolism assessments?
Are ventilation nuclear medicine lung scans really needed in cases of suspecte...Read more on AuntMinnie.comRelated Reading:
SNMMI pushes for coverage of PET tracers for Aduhelm use
SNMMI issues new guidelines on V/Q scans
SNMMI urges fast-track review of Technegas for V/Q scans
SNMMI updates ventilation study guidance
SNMMI 2020: How nuclear medicine handled COVID-19 (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 12, 2021 Category: Radiology Source Type: news
Home treatment cost saving in stable patients with pulmonary embolism
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 1, 2021 Category: Drugs & Pharmacology Source Type: news
SIIM, RSNA, others partner on COVID-19 AI challenge
A machine-learning challenge to promote the development of algorithms for th...Read more on AuntMinnie.comRelated Reading:
MIDRC offers support for COVID-19 AI
AMVC Spring 2021: MIDRC project targets AI challenges of COVID-19
Imaging groups take stand against AI deregulation
RSNA announces pulmonary embolism challenge winners
C-MIMI: Use of AI in radiology is evolving (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 18, 2021 Category: Radiology Source Type: news
Latest Trends in the Management of Pulmonary Embolism Latest Trends in the Management of Pulmonary Embolism
Following clinical management of cancer-associated VTE in the hospital, direct oral anticoagulant therapy at discharge is your starting point, except in cases of intact luminal cancers.Medscape Medical News (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - May 11, 2021 Category: Intensive Care Tags: Hospital Medicine News Source Type: news
Management of Acute Pulmonary Embolism With a PE Response Team Management of Acute Pulmonary Embolism With a PE Response Team
This article provides an overview of the PERT process, highlighting risk stratification and treatment.Journal of the American Board of Family Medicine (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - May 10, 2021 Category: Intensive Care Tags: Family Medicine/Primary Care Journal Article Source Type: news
Study finds up to 24 percent of esophagectomy patients can develop VTE post-operatively
(American Association for Thoracic Surgery) A new study presented today at the AATS 101st Annual Meeting, found that the percentage of patients undergoing esophagectomy for cancer who suffer Venous Thromboembolism (VTE) post-operatively is much higher than previously reported, with as many as 24 percent suffering from Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE). Six-month mortality for patients with VTE was 17.6 percent compared to 2.1 percent for those without. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 1, 2021 Category: International Medicine & Public Health Source Type: news
Johnson & Johnson Single-Shot COVID-19 Vaccinations to Resume in the U.S. for All Adults Aged 18 and Older Following CDC and FDA Decision
NEW BRUNSWICK, N.J., April 23, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that vaccinations with the Company’s COVID-19 single-shot vaccine will resume for all adults aged 18 years and older in the U.S., under Emergency Use Authorization (EUA), following a decision from the United States Centers for Disease Control (CDC) and Food and Drug Administration (FDA).The decision was based on a recommendation from the U.S. CDC Advisory Committee on Immunization Practices (ACIP), which followed a rigorous evaluation of data relating to a very rare adverse event involving blood clots in combination wi...
Source: Johnson and Johnson - April 23, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Johnson & Johnson COVID-19 Vaccine Roll-out to Resume in Europe Following European Medicines Agency (EMA) ReviewEMA Confirms Overall Benefit-Risk Profile Remains Positive
NEW BRUNSWICK, N.J., April 20, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has provided updated guidance for use of the Company’s COVID-19 vaccine and confirmed the overall benefit-risk profile remains positive. The guidance follows PRAC review of a small number of cases of a very rare adverse event involving blood clots in combination with low platelet counts that can occur within approximately one to three weeks following injection with the Company’s COVID-19 vaccine. As a result, Johnson &...
Source: Johnson and Johnson - April 20, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Imbio signs Heart&Lung Health in U.K.
Artificial intelligence software developer Imbio has signed a deal with U.K...Read more on AuntMinnie.comRelated Reading:
Imbio nets FDA nod for RV/LV Analysis AI algorithm
Aidoc and Imbio team up on AI for pulmonary embolism
Siemens adds Imbio AI apps to syngo.via platform
Imbio teams up with Genentech for AI in lung disease
Imbio adds analysis software to Nuance AI marketplace (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 6, 2021 Category: Radiology Source Type: news
